Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol by Raleigh, S M et al.
Retinoids, analogues of vitamin A, are among the few substances
which have been shown unequivocally in clinical trials to prevent
epithelial cancers in humans (Lotan, 1996). The encouraging trial
results have stimulated considerable interest in the mechanism of
action, clinical pharmacology and toxicology of the retinoids. One
of the most efficacious retinoids from the standpoint of chemo-
preventive potency is isotretinoin (13-cis-retinoic acid). It caused
significant remissions of oral premalignant diseases (Hong et al,
1990) and reduced the occurrence of second primary tumours in
patients treated previously by surgery or radiotherapy for squamous
cell carcinoma of the head and neck (Hong et al, 1986). Isotretinoin
has also been investigated for its potential clinical usefulness both
in the prevention of lung cancer in patients with bronchial squa-
mous metaplasia (Lee et al, 1994) and as a therapeutic agent in
patients with advanced non-small cell lung cancer (Grunberg and
Itri, 1987). Unfortunately the use of retinoids such as isotretinoin in
the prevention or treatment of malignancies of the aerodigestive
tract poses problems of tolerability. Many patients enrolled into
chemoprevention trials have been unable to tolerate doses of 1 mg
kg–1 isotretinoin for periods exceeding 6 months, because of
adverse dermatological effects such as dry skin, itching, skin
flaking, nasal stuffiness, xerostomia and cheilitis. These reactions
can be ameliorated with topical lubricants and moisturizing agents.
However, in some patients these detrimental effects interfere with
compliance and dose reduction is required (Warrell et al, 1995).
Other manifestations of toxicity associated with retinoid treatment
are headaches, hypertriglyceridaemia, formation of hyperostosis,
hypercalcaemia and hepatic damage as reflected by a transient
increase in serum transaminases, alkaline phosphatases and/or
bilirubin. Furthermore, retinoids are potent teratogens. This toxi-
city spectrum necessitates pharmaceutical strategies which target
retinoids to the tissue in which the malignancy is to be prevented,
thus reducing systemic exposure.
Delivery of drugs to the lungs via aerosol administration has
long been practised successfully in areas of therapy other than
cancer, especially in the treatment of asthma. This mode of
targeted delivery offers a potentially attractive approach to mini-
mizing the systemic toxicity associated with oral or percutanous
application of chemopreventive agents (Wattenberg et al, 1997).
Intriguingly, it is also under investigation as a strategy to achieve a
better therapeutic ratio for agents such as doxorubicin and pacli-
taxel in the treatment of lung cancer (Vail et al, 1999). Using the
rat as experimental model we wished to test the hypothesis that
delivery of isotretinoin as an aerosol is a viable strategy in its
clinical development as a lung cancer chemopreventive drug. Like
most retinoids, isotretinoin is water-insoluble, therefore it was
formulated for this study as a powder aerosol, based on the realiza-
tion that the technology pertinent to dry powder inhalation is
advancing rapidly (Clark, 1995; Virchow et al, 1994). We also
wanted to assess whether delivering isotretinoin via an aerosol to
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ally militate against the use of this route of administration in the
clinic.
MATERIALS AND METHODS
Isotretinoin formulation
Isotretinoin was purchased from BASF (Mannheim, Germany)
and determined as > 99% pure by high-pressure liquid chromato-
graphic (HPLC) analysis. Drug was dissolved in DMSO,
cremophor, propylene glycol and water (20:8:10:62) for adminis-
tration by gavage. In the inhalation study a mixture of isotretinoin
and dextrose (2 or 10%) was used. The components of this mixture
were carefully milled using a centrifugal mill and formulated in
the absence of light. The aerosol powder was analysed using a
low-angle laser light-scattering particle sizer (Malvern Mastersizer
X) or an ISI Aerodynamic Particle Sizer and Diluter (ISI
Incorporated, MIN). The aerosol particle size distribution was
characterized by aerodynamic diameters between 1 and 5 mm with
a mass median aerodynamic diameter (MMAD) of 3.4 mm. In
order to determine the respirable fraction of the aerosol formula-
tion a single-stage impinger was operated to provide a pressure
drop of 4 kPa across the dry powder container. The respirable frac-
tion, which under these conditions comprises particles with a
MMAD of below approximately 6 mm, was determined as 22 ±
3% (mean ± SD of n = 3).
Animals
Female F344 rats (160 ± 10 g), supplied by Harlan UK Ltd
(Bicester, UK), were maintained in negative pressure isolators and
given food and water ad libitum thoughout the study. Animal
husbandry was in accordance with the animal welfare guidelines
stipulated by the UK Home Office and the MRC, and the project
has been approved by the Leicester University Ethical Review and
Animal Welfare Committee.
Inhalation exposure
Groups of four rats were exposed to the isotretinoin powder
aerosol under subdued lighting for periods of 5, 10, 20 or 40 min
in a nose-only inhalation chamber. Animals were placed in
restraining cones in the inhalation chamber, which was tightly
linked to a specially engineered perspex elutriator. Powder aerosol
was pushed into the bottom of the elutriator through a side arm, 
to which a powder-filled decapitated 50 ml plastic syringe was
attached. The movement of the plunger was controlled by an auto-
matic timing device linked to a syringe pump (Razel Scientific
Instruments Inc, Stanford, CA, USA). Delivery of powder aerosol
into the elutriator was pulsed for 20-s periods every 2.5 min during
the entire exposure period. The powder was distributed by air,
pumped at a flow rate of approximately 10 l min–1, into the elutri-
ator through three entry points at its base. The particle load in the
air reaching the rats was measured gravimetrically for the duration
of exposure with a collection filter assembly containing a
Millipore filter placed in an empty nose cone, through which air
was drawn at 100, 250 or 1000 ml min–1. In several experiments
the isotretinoin content in the mixture was checked by HPLC
analysis. The concentration of isotretinoin in the air was 0.26 ±
0.12 mg l–1 of air in 20 exposures during the low-dose inhalation
experiments using the 2% isotretinoin formulation, and 2.4 ± 0.8
mg l–1 (mean ± SD) of air in 30 exposures during the high-dose
inhalation experiments using the 10% isotretinoin formulation.
Animals were subjected to either a single exposure to the aerosol
powder or repeated exposure for 5–10 days. Care was taken to
remove aerosol powder from the animals’ fur by exposing them 
to a directed stream of air for 30 s after their removal from the
inhalation chamber. Nevertheless, some powder aerosol remained
visibly in the fur surrounding the animals’ head and was thus
available for oral ingestion by the animals when they groomed
themselves post-exposure. Therefore isotretinoin levels after
inhalation reflect a composite of inhaled and some orally ingested
compound. It is likely that the oral component of this composite
affects isotretinoin levels in the plasma more prominently than
those in the lungs. In some experiments animals remained in the
restraining cages up to the time of killing in order to minimize oral
ingestion. The dose administered via inhalation was estimated
from the aerosol concentration, amount of isotretinoin per litre of
air and respiratory minute volume (RMV) for the rat (Guyton,
1947), by the following formula:
dose = aerosol concentration ´ RMV ´ exposure time ´ body
weight–1
The assumption of this approach is that the inspired aerosol is
deposited completely in the lungs. Therefore, the doses referred to
in the following in the context of the inhalation experiments have
to be viewed as ‘theoretical’ doses.
Oral dosing
Groups of at least four rats received isotretinoin by gastric lavage
once or repeatedly for 14 days. The oral doses were 0.5, 1 and 
10 mg kg–1.
Sample preparation, HPLC analysis and measurement
of the area under the drug concentration-vs-time curve
(AUC)
In the oral administration study animals were killed at 0.5, 1, 6 and
24 h after gavage, in some experiments 2, 4 and 48 h points were
included. In the inhalation study rats were killed at 0.25, 0.5, 1, 2
and 4 h after completion of the final exposure. Blood was obtained
by cardiac puncture under terminal anaesthesia, collected into
heparinized tubes and centrifuged to yield plasma. Lung tissue was
excised and weighed, and plasma and tissue were stored at –80°C
until analysis. Retinoids were extracted from tissue and plasma
into an equal volume of hexane and quantitated by a normal phase
HPLC method with UV detection as described by Lanvers et al
(1996) using arotenoid ethylsulphone as internal standard. The
internal standard and reference material for the isotretinoin
metabolite-4-oxo-isotretinoin were kindly provided by M Klaus
(Hoffmann-La Roche, Basel, Switzerland). A destructive
sampling scheme was employed. The mean areas under the plasma
or lung concentration vs time curves (AUC) between 0 and 24 h in
the case of the oral administration, or from 0–4 or 6 h for the
inhalation exposure study were computed from the mean plasma
and tissue levels by the trapezoidal rule (Rowland and Tozer,
1995). Standard errors for the AUC values were calculated from
the variances of drug/metabolite levels at individual time points
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following formula (Gagnon and Peterson, 1998):
Variance (AUC) = S [(trapezoidal weights2) ´ (variance of
values at each time-point ´ n–1)]
Values of peak levels and doses quoted in the Results represent the
mean ± SD.
Toxicology
Groups of four rats each were exposed to either milled dextrose
powder, the excipient in the isotretinoin aerosol formulation, or to
the isotretinoin powder, repeatedly for 5 days (high-dose) or 10
days (low-dose). Each exposure period was 5 min, and animal
weights were recorded daily. The theoretical doses were approxi-
mately 10 mg kg–1 isotretinoin with 90 mg kg–1 dextrose in the
high-dose experiments (10% formulation) and 2 mg kg–1
isotretinoin with 120 mg kg–1 dextrose in the low-dose experi-
ments (2% formulation). In control experiments equivalent doses
of dextrose only were inhaled. Animals were killed 1, 3 or 7 days
after completion of the final inhalation exposure. Lung, liver,
kidney, thymus, pancreas, spleen, heart, skin, oesophagus and
stomach tissues were removed and fixed in buffered formalin and
stained with haematoxylin and eosin for histopathological
examination by light microscopy. Concentrations of alkaline
phosphatase (ALP) in the plasma were determined using an ALP
Optimized Kit (Sigma Chemical Company, Poole, UK).
RESULTS
Lung levels of isotretinoin after powder aerosol
administration
The suitability of isotretinoin formulated with dextrose as a
powder aerosol for inhalation was tested in rats which inhaled
isotretinoin at either low or high theoretical doses, which were
approximately 1 mg kg–1 and 10 mg kg–1, respectively. Figure 1
shows that inhalation of the aerosol furnished measurable
isotretinoin levels in the lung. Isotretinoin was also found in the
plasma. Isomerization of the drug to all-trans- or 9-cis-retinoic
acids was not observed either in the lungs or the plasma (not
shown), but in the high-dose exposure experiments, the isotretinoin
metabolite 4-oxo-isotretinoin was found. The AUC(0–4 h) values for
isotretinoin in the lungs increased linearly with inhalation dose
after single exposure (Figure 2), which indicates that the adminis-
tered dose increased proportionally with exposure time. Even
though the linearity of this relationship was less obvious after
repeated dosing (Figure 2), these results suggest broadly linear
pharmacokinetics for inhaled isotretinoin at the dose-range admin-
istered in this study, supporting the potential feasibility of this
approach.
Comparison of aerosol and oral administration of
isotretinoin
Animals also received isotretinoin by gavage at low (0.5 mg kg–1
single, 1 mg kg–1 repeated) and high (10 mg kg–1 single or repeated)
doses in order to allow comparison of lung and plasma levels after
inhalation exposure with those seen after the conventional mode of
isotretinoin administration. The lung concentration-vs-time curves
in Figure 1 indicate higher concentrations of isotretinoin in the
lungs after aerosol administration at both low (Figure 1A) and high
doses (Figure 1B) compared to those achieved after oral adminis-
tration of the drug at comparable doses.
Comparison of the corresponding AUC and Cmax values in lung
tissue and plasma suggests that drug availability was higher in the
lungs following aerosol administration at both dose-levels (see
Table 1). Figure 3 shows the ratios of mean lung AUC or Cmax
Lung delivery of isotretinoin powder aerosol 937
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Figure 1 Isotretinoin levels in rat lung after administration of isotretinoin
either at a low (A) or high dose (B), given orally (a, c) as a single dose (a) or
daily for 14 days (c), or after termination of exposure to isotretinoin powder
aerosol (b, d) given once (b) or repeatedly (d), daily for 10 (A) or 7 days (B).
The doses were as follows: (A) oral dose 0.5 once or 1 mg kg–1 repeatedly;
inhalation exposure to the 2% isotretinoin powder formulation for 5 min once
or repeatedly (theoretical dose approximately 1 mg kg–1); (B) oral dose 
10 mg kg–1 once or repeatedly, inhalation exposure to the 10% isotretinoin
powder formulation for 5 min once or repeatedly (theoretical dose
approximately 10 mg kg–1). Values are the mean ± SD of four animalsvalues of drug over mean plasma AUC or Cmax values, measured
after single or repeated administration by either the oral or inhala-
tion routes. The ratios of the AUCs in the aerosol exposures
exceed those computed for the oral route by factors of between
two in the case of the single low-dose to five for the single high-
dose. Similarly the ratios for the Cmax values obtained in the
aerosol exposures surpass those seen after p.o. administration by
factors of between two and eight.
In additional experiments, rats underwent single exposure to
isotretinoin powder aerosol at a range of higher-dose levels up to
approximately 40 mg kg–1, and the resultant ratios of mean lung
isotretinoin AUC or Cmax values over mean plasma isotretinoin
AUC or Cmax values were consistently 3- to 8-fold higher than
those computed for the high oral dose (results not shown).
Surprisingly, plasma isotretinoin levels after aerosol administra-
tion were similar to, or even above, those after oral dosing. This
finding is most likely a corollary of the fact that plasma levels after
inhalation reflect a composite of inhaled and ingested isotretinoin.
As described in Methods, when the rats groomed themselves post-
exposure, they ingested isotretinoin powder which had inevitably
been lodged in the fur around the neck during the inhalation
period. Therefore, plasma levels post-aerosol delivery in the rat
are likely to overestimate systemic bioavailibility of the
isotretinoin aerosol as an intrinsic consequence of the experi-
mental design.
Comparison of the levels and AUC values depicted in Figures 1
and 3 intimates that concentrations achieved in the lungs after
repeated high doses of isotretinoin were lower than those obtained
after single administration, irrespective of route of administration.
This difference suggests that prolonged exposure to high doses of
isotretinoin does not lead to accumulation of the drug in rat lung.
Levels of the isotretinoin metabolite 4-oxo-isotretinoin were
938 SM Raleigh et al
British Journal of Cancer (2000) 83(7), 935–940 © 2000 Cancer Research Campaign
300
200
100
0
A
U
C
 
(
n
m
o
l
 
h
 
 
g
–
1
)
B
60
30
0
5
2
5
10
10
10
A
5
2
5
10
10
10
40
10
20
10
Exposure time (min)
Isotretinoin content (%)
Figure 2 Relationship between isotretinoin inhalation dose and isotretinoin lung AUC values after single (A) or repeat exposure (B) of rats to the isotretinoin
powder aerosol. Lung AUC(0–4 h) values were calculated from lung-concentration-vs-time curves with five time-points after termination of exposure. Numbers of
multiple daily exposures in (B) were 10 for the lowest dose, five for the intermediate and seven for the highest daily dose. Error bars for the AUC values were
derived from the variances of the individual time points. The individual isotretinoin lung level data points in the lung-concentration-vs-time curves were
characterized by SDs varying between 18 and 55% of the mean. Regression analysis of the line in (A) furnishes a coefficient of 0.9879
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Dose Route AUCplasma AUClung Cmax, plasma Cmax, lung
(nmol h ml–1) (nmol h g–1) (nmol ml–1) (nmol g–1)
Low single p.o. 0.96 ± 0.006 0.14 ± 0.10 0.38 ± 0.05 0.06 ± 0.05
aerosol 1.44 ± 0.13 0.39 ± 0.05 0.36 ± 0.08 0.15 ± 0.07
High single p.o. 35.0 ± 3.2 12 ± 2 12.1 ± 1.0 4.0 ± 1.1
aerosol 40 ± 6 72 ± 12 14.0 ± 9.0 33 ± 14
Low repeated p.o. 0.73 ± 0.06 0.03 ± 0.02 0.23 ± 0.11 0.04 ± 0.03
aerosol 2.10 ± 0.47 0.84 ± 0.15 0.67 ± 0.85 0.51 ± 0.10
High repeated p.o. 15.1 ± 1.7 3.3 ± 0.7 5.7 ± 3.7 0.7 ± 0.6
aerosol 50.1 ± 7.8 45.9 ± 4.6 22.1 ± 17.0 23.3 ± 6.3
Figure 3 Ratios of mean AUC(0–4 h) values of isotretinoin in the lung (AUClung) over mean AUC(0–24 h) values in the plasma (AUCplasma) (A), and ratios of mean
peak concentrations of isotretinoin in the lung (Cmax, lung) over those in the plasma (Cmax, plasma) (B), in rats after administration of isotretinoin p.o. (open bars) or by
inhalation of powder aerosol (closed bars). Isotretinoin was given at a low or high dose once or repeatedly. Table 1 shows the AUC and Cmax values used for the
ratio calculation. The doses were as follows: (A) oral dose 0.5 once and 1 mg kg–1 daily for 14 days; inhalation exposure to the 2% isotretinoin powder
formulation for 5 min once or daily for 10 days (theoretical dose approximately 1 mg kg–1); (B) oral dose 10 mg kg–1 once or daily for 14 days, and inhalation
exposure to the 10% isotretinoin powder formulation for 5 min once or daily for 7 days (theoretical dose approximately 10 mg kg–1)below the limit of quantitation after the single oral high dose of
isotretinoin, whereas after multiple oral dosing the lung AUC of 4-
oxo-isotretinoin was 5.1 ± 0.4 nmol h g–1 tissue (mean ± SD of n =
3). For the single inhalation exposure at the high dose, the lung
AUC for 4-oxo-isotretinoin was 4.5 ± 1.2 nmol h g–1, the corre-
sponding value after multiple exposure was 7.4 ± 1.5 nmol h g–1,
constituting an increase of 64% over single dosing. A similar
elevation was seen in plasma 4-oxo-isotretinoin levels. Thus the 4-
oxo-isotretinoin AUC values inversely mirror the changes in
parent drug AUC described above, in that they were considerably
higher after repeated than after single doses of isotretinoin. These
data are consistent with the notion that – irrespective of route of
administration – prolonged exposure to high concentrations of
isotretinoin, at least in the rat, induces its own metabolic disposal.
Safety of isotretinoin powder aerosol
We wished to assess, in a preliminary fashion, the safety of the
isotretinoin powder aerosol in order to allow judgement as to the
feasibilty of its potential development for clinical trial. To that end
animals were exposed to the aerosol powder once or daily for
either 5 or 10 consecutive days. Control animals inhaled dextrose,
the excipient used in the aerosol formulation. Lung, liver, kidney,
thymus, pancreas, spleen, heart, skin, oesophagus and stomach
tissues did not show any signs of aerosol-induced morphological
alterations. Animals which received the high dose of isotretinoin
aerosol (10% isotretinoin formulation for 5 min) daily for 5 days
started to lose weight after the fourth dose, with the weight nadir
occurring on day 7, two days after termination of exposure, by
which time they had lost a mean of 12% of their body weight.
Subsequently, they commenced to gain weight again. Control rats
exposed to dextrose powder only, animals exposed to isotretinoin
powder aerosol at the low dose (2% isotretinoin formulation for 
5 min daily) for 10 days, or animals which received 10 mg kg–1
isotretinoin p.o. for 14 days did not lose weight. Plasma ALP
activity was measured immediately after the final exposure of rats
to 2% isotretinoin aerosol for 5 min periods on 10 consecutive
days. ALP concentrations in units L–1 were 201 ± 8 (n = 8) in
control rats, 202 ± 5 (n = 13) in dextrose-exposed animals and 
275 ± 6 (n = 29) in rats exposed to isotretinoin, which constitutes a
modest but significant increase of 36% compared to controls (P <
0.001). Elevation of ALP activity in the plasma has been shown in
the original toxicity study of isotretinoin in rats at doses of 
4 mg kg–1 or more given p.o. daily for 4 weeks, and this elevation
has been tentatively associated with the effects of excess vitamin
A on bone (Hixson et al, 1979).
DISCUSSION
The work outlined above describes, for the first time, the use of a
powder aerosol formulation as a delivery system for a lung cancer
chemopreventive agent. The pharmaceutical arguments in favour
of designing a powder aerosol to target drugs to the lungs are
compelling. They include the physical and chemical stability of
the active ingredient in a powder formulation, uniformity and
reproducibility of the inhaled dose and deep-lung penetration of
the inhaled small drug particles. These considerations are espe-
cially pertinent for agents such as isotretinoin, which is highly
water-insoluble and exquisitely susceptible to light-induced
decomposition when dissolved. The results described in this paper
show clearly that the ratios of drug concentrations in the lungs
over those in the plasma were invariably higher after inhalation
than after oral administration. This difference was observed irre-
spective of the magnitude of dose administered or of whether ratio
computation was based on AUC or peak concentration values.
Furthermore, repeated aerosol administration was not confounded
by drug accumulation in the lungs. Thus the study supports the
hypothesis that for the chemoprevention of malignancies of the
upper aerodigestive tract inhalation of isotretinoin powder aerosol
is preferable to its oral administration, because the aerosol yields a
superior pharmacokinetic profile.
It is important to consider how the isotretinoin concentrations
observed in this study in rats compare with those achievable in
humans. A single oral dose of 0.5 mg kg–1 isotretinoin in humans
resulted in a mean peak plasma concentration of 0.83 nmol ml–1
(Kerr et al, 1982). The plasma levels described here in rats, 1.5 nmol
ml–1 and 0.4 nmol ml–1 after low oral or aerosol inhalation doses,
respectively, are of the same order of magnitude. The ratios of lung
to plasma drug levels observed here in rats may well be representa-
tive of other species and not restricted to this animal model. For
example, published isotretinoin peak levels in the lungs and plasma
of mice after isotretinoin 10 mg kg–1 p.o. (Kalin et al, 1982) permit
calculation of a ratio of mean peak lung to plasma concentrations of
0.24, compared to 0.34 described here for the same oral dose in the
rat. Applying this ratio to a speculative computation of peak lung
levels in humans after the 0.5 mg kg–1 oral dose of isotretinoin yields
approximately 0.20 nmol isotretinoin per gram of lung. If inhalation
of isotretinoin in humans leads to lung levels similar to those seen in
our rats after repeated inhalation administration of the low dose, one
could expect human peak lung levels at least 2.5-fold higher than
those seen after oral medication. This value is probably a consider-
able underestimate, as exposure of rats to a therapeutic aerosol in an
inhalation chamber is undoubtedly an imperfect model for human
aerosol administration. Nevertheless, concentrations of isotretinoin
of this order of magnitude achieved repeatedly in human lungs may
be sufficient to prevent cancer. Most of the effects of retinoids are
mediated via the retinoic acid receptors (RAR) and retinoid X recep-
tors (RXR), nuclear steroid hormone receptors which act as tran-
scription factors. Upregulation of one specific receptor type,
RAR-b, has been correlated with the chemopreventive efficacy of
retinoids (Ahn et al, 1995; Lotan et al, 1995). In experiments in
human bronchial epithelial cells in vitro upregulation of RAR-b
protein expression was elicited by 2 nmol ml–1 retinoic acid within a
12 h period (Boyle et al, 1999). The present study indicates that
concentrations of this order of magnitude might be achievable in
human lung tissue after inhalation of isotretinoin. Ultimately, the
contention that chemopreventive levels of isotretinoin can be
achieved in the human lung after aerosol delivery remains to be
investigated in the clinic.
The observations made here as to the feasibility of delivery of
chemopreventive agents via powder aerosol complement the
conclusions drawn from two recent preclinical studies in which the
glucocorticoid budesonide and the isotretinoin isomer all-trans
retinoic acid (ATRA) have been administered as liquid aerosols via
the inhalation route. Exposure of mice to aerosolized budesonide
significantly inhibited formation of benzo(a)pyrene-induced
pulmonary adenomas (Wattenberg et al, 1997), and inhalation by
mice of ATRA liposomes induced both the concentration and
activity of transglutaminase in alveolar macrophages (Partha-
sarathy et al, 1999). The latter study differs from ours in that
Lung delivery of isotretinoin powder aerosol 939
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detectable drug levels only in the lungs, but not in the plasma. In
contrast, isotretinoin powder aerosol administration led to measur-
able retinoid levels also in the plasma. This discrepancy could be
related to differences in absorption from the gastrointestinal tract
of retinoid ingested orally during aerosol exposure. It is conceiv-
able that absorption of liposomally entrapped ATRA in the study
by Parthasarathy et al (1999) was much more limited than that of
powdered isotretinoin. We believe that the advantageous pharma-
ceutical properties of a dry powder formulation as compared to
liposomes suspended in liquid with potentially complicated
stability and drug-release characteristics should be considered
carefully when the retinoid aerosol formulations are eventually
evaluated for advancement into clinical development.
Animals which inhaled isotretinoin aerosol powder repeatedly
at the high dose suffered moderate weight loss. In contrast,
repeated administration of a comparable oral dose did not elicit
this effect. The basis of the drug-induced weight loss after inhala-
tion exposure of high-dose isotretinoin could not be established, as
it was not matched by significant alterations in the morphology of
a variety of organs which were investigated. Importantly, our
studies render it unlikely that the lungs are the source of this
adverse effect. Nevertheless, the possibility of unexpected adverse
effects specific to lung delivery has to be borne in mind when
future clinical trials of isotretinoin powder aerosol are planned.
Targeting agents to the desired site of action is a priority area in
the portfolio of strategies currently being pursued in the optimiza-
tion of the development of cancer chemopreventive drugs. The
work outlined here in concert with related recent studies
(Wattenberg et al, 1997; Parthasarathy et al, 1999) suggests that
specific delivery of agents to the lungs for chemoprevention of
lung cancer is an attractive and exciting option, at least for gluco-
corticoids and retinoids.
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